146 related articles for article (PubMed ID: 32151680)
1. Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain.
Brouillette RL; Besserer-Offroy É; Mona CE; Chartier M; Lavenus S; Sousbie M; Belleville K; Longpré JM; Marsault É; Grandbois M; Sarret P
Pharmacol Res; 2020 May; 155():104750. PubMed ID: 32151680
[TBL] [Abstract][Full Text] [Related]
2. The signaling signature of the neurotensin type 1 receptor with endogenous ligands.
Besserer-Offroy É; Brouillette RL; Lavenus S; Froehlich U; Brumwell A; Murza A; Longpré JM; Marsault É; Grandbois M; Sarret P; Leduc R
Eur J Pharmacol; 2017 Jun; 805():1-13. PubMed ID: 28341345
[TBL] [Abstract][Full Text] [Related]
3. Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog.
Tétreault P; Besserer-Offroy É; Brouillette RL; René A; Murza A; Fanelli R; Kirby K; Parent AJ; Dubuc I; Beaudet N; Côté J; Longpré JM; Martinez J; Cavelier F; Sarret P
Eur J Pharmacol; 2020 Sep; 882():173174. PubMed ID: 32534076
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity.
Roussy G; Dansereau MA; Baudisson S; Ezzoubaa F; Belleville K; Beaudet N; Martinez J; Richelson E; Sarret P
Mol Pain; 2009 Jul; 5():38. PubMed ID: 19580660
[TBL] [Abstract][Full Text] [Related]
5. Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model.
Roussy G; Dansereau MA; Doré-Savard L; Belleville K; Beaudet N; Richelson E; Sarret P
J Neurochem; 2008 May; 105(4):1100-14. PubMed ID: 18182046
[TBL] [Abstract][Full Text] [Related]
6. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia.
Vivancos M; Fanelli R; Besserer-Offroy É; Beaulieu S; Chartier M; Resua-Rojas M; Mona CE; Previti S; Rémond E; Longpré JM; Cavelier F; Sarret P
Behav Brain Res; 2021 May; 405():113189. PubMed ID: 33607165
[TBL] [Abstract][Full Text] [Related]
7. Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia.
Eiselt E; Gonzalez S; Martin C; Chartier M; Betti C; Longpré JM; Cavelier F; Tourwé D; Gendron L; Ballet S; Sarret P
ACS Chem Neurosci; 2019 Nov; 10(11):4535-4544. PubMed ID: 31589400
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain.
Guillemette A; Dansereau MA; Beaudet N; Richelson E; Sarret P
Eur J Pain; 2012 Apr; 16(4):473-84. PubMed ID: 22396077
[TBL] [Abstract][Full Text] [Related]
9. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors.
Sarret P; Esdaile MJ; Perron A; Martinez J; Stroh T; Beaudet A
J Neurosci; 2005 Sep; 25(36):8188-96. PubMed ID: 16148226
[TBL] [Abstract][Full Text] [Related]
10. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins.
Sevigny LM; Zhang P; Bohm A; Lazarides K; Perides G; Covic L; Kuliopulos A
Proc Natl Acad Sci U S A; 2011 May; 108(20):8491-6. PubMed ID: 21536878
[TBL] [Abstract][Full Text] [Related]
11. A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead.
Winther M; Gabl M; Welin A; Dahlgren C; Forsman H
FEBS Lett; 2015 Jul; 589(15):1832-9. PubMed ID: 26071379
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog.
Chartier M; Desgagné M; Sousbie M; Rumsby C; Chevillard L; Théroux L; Haroune L; Côté J; Longpré JM; Boudreault PL; Marsault É; Sarret P
Biomed Pharmacother; 2021 Sep; 141():111861. PubMed ID: 34229249
[TBL] [Abstract][Full Text] [Related]
13. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein.
Quoyer J; Janz JM; Luo J; Ren Y; Armando S; Lukashova V; Benovic JL; Carlson KE; Hunt SW; Bouvier M
Proc Natl Acad Sci U S A; 2013 Dec; 110(52):E5088-97. PubMed ID: 24309376
[TBL] [Abstract][Full Text] [Related]
14. Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics.
Zhang P; Covic L; Kuliopulos A
Methods Mol Biol; 2015; 1324():191-203. PubMed ID: 26202271
[TBL] [Abstract][Full Text] [Related]
15. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a CCR2-targeting pepducin therapy for chronic pain.
Midavaine É; Brouillette RL; Théberge E; Mona CE; Kashem SW; Côté J; Zeugin V; Besserer-Offroy É; Longpré JM; Marsault É; Sarret P
Pharmacol Res; 2024 Jul; 205():107242. PubMed ID: 38823470
[TBL] [Abstract][Full Text] [Related]
17. Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics.
Zhang P; Leger AJ; Baleja JD; Rana R; Corlin T; Nguyen N; Koukos G; Bohm A; Covic L; Kuliopulos A
J Biol Chem; 2015 Jun; 290(25):15785-15798. PubMed ID: 25934391
[TBL] [Abstract][Full Text] [Related]
18. Altered morphine-induced analgesia in neurotensin type 1 receptor null mice.
Roussy G; Beaudry H; Lafrance M; Belleville K; Beaudet N; Wada K; Gendron L; Sarret P
Neuroscience; 2010 Nov; 170(4):1286-94. PubMed ID: 20727387
[TBL] [Abstract][Full Text] [Related]
19. Lipopeptide Pepducins as Therapeutic Agents.
Michael E; Covic L; Kuliopulos A
Methods Mol Biol; 2022; 2383():307-333. PubMed ID: 34766299
[TBL] [Abstract][Full Text] [Related]
20. Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question.
Winther M; Holdfeldt A; Sundqvist M; Rajabkhani Z; Gabl M; Bylund J; Dahlgren C; Forsman H
PLoS One; 2017; 12(9):e0185132. PubMed ID: 28934373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
